MedPath

Popliteal Sciatic Nerve Block: Intraneural or Extraneural?

Phase 4
Completed
Conditions
Hallux Valgus
Interventions
Procedure: Intraneural injection
Procedure: Extraneural injection
Device: PAJUNK SonoPlex 22G needle.
Registration Number
NCT01987128
Lead Sponsor
ASST Gaetano Pini-CTO
Brief Summary

Aim of this study is to demonstrate the advantages of intraneural injection over extraneural injection in terms of onset and duration on peripheral block. In addition we will evaluate the frequency of possible adverse effects.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
88
Inclusion Criteria
  • ASA I-II
Exclusion Criteria
  • Neurological diseases
  • Diabetes
  • Allergies to used drugs
  • Chronic pain in treatment
  • Electrophysiological alterations at time zero analysis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intraneural injectionIntraneural injectionAll patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
Intraneural injectionPAJUNK SonoPlex 22G needle.All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
extraneural injectionExtraneural injectionAll patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
extraneural injectionPAJUNK SonoPlex 22G needle.All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
Intraneural injectionRopivacaineAll patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
extraneural injectionRopivacaineAll patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
Primary Outcome Measures
NameTimeMethod
onset timeevery 2 minutes for a maximum of 30 minutes

Pinprick test evaluation on sciatic nerve territory:

With a 22G needle the blinded operator will assess sensitiveness to puncture and then assign a score every 2 minutes for 30 minutes. A score of 0 will describe no sensation to puncture, on the other hand a score of 1 will be assigned if sensation to puncture is still present.

Evaluation of motor blockade:

Plantar and dorsal flexion of the foot will be evaluated for motor blockade of sciatic nerve. A score of 1 will be assigned if foot movement is conserved, 2 if is impaired and 3 when disappears.

Onset time is described as the time at which pinprick score turns to 0 and motor blockade score turns to 3.

Secondary Outcome Measures
NameTimeMethod
success rate in each groupat 30 minutes

Success rate is described as the percentage of subjects with an onset time within 30 minutes in a group among all subjects treated in that group

Nerve injuries1, 5 weeks and at 6 months after surgery

Neurophysiological and clinic evaluation will be assessed either with clinical examination and electrophysiological tests by a neurophysiologist eventually evidencing any movement impairment or dysesthesia in the sciatic territory.

Trial Locations

Locations (1)

Istituto Ortopedico G. Pini

🇮🇹

Milan, Milano, Italy

© Copyright 2025. All Rights Reserved by MedPath